The GSK3A Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited population of Jurkat T lymphocytes with disrupted GSK3A gene expression, providing a loss-of-function model in a human immune cell context. This polyclonal product eliminates wild-type GSK3A protein while preserving cellular heterogeneity, ideal for high-throughput screening, bulk biochemical analyses, and signaling studies. CRISPR/Cas9-mediated gene disruption ensures loss of GSK3A function.
Jurkat cells, an immortalized human T lymphocyte line derived from the peripheral blood of an acute T cell leukemia patient, serve as the host system. These suspension-adapted cells express CD3, CD4, and a functional T cell receptor, making them a cornerstone model for T cell receptor signaling, cytokine secretion, and immune synapse formation. Their rapid growth, high transfectability, and well-characterized genomic landscape facilitate reproducible genetic manipulation and downstream assays. The Jurkat background is particularly relevant for oncology research, as it retains many features of the original leukemic transformation, including constitutive activation of certain signaling cascades.
GSK3A encodes a ubiquitously expressed serine/threonine kinase that acts as a central node in Wnt, insulin, and Hedgehog pathways. In unstimulated cells, GSK3A constitutively phosphorylates glycogen synthase (GYS1) and participates in a multiprotein complex with Axin, APC, and CK1?? to target ??-catenin for degradation. Upon Wnt stimulation, Frizzled receptor and LRP5/6 engagement recruits Dishevelled (DVL) to inhibit GSK3A via AKT- or PKA-mediated phosphorylation at Ser21, stabilizing ??-catenin to drive TCF/LEF-dependent transcription of genes such as c-Myc and Cyclin D1. GSK3A also integrates insulin signaling through PI3K/AKT-mediated inhibition and cross-talks with mTOR and Hedgehog modules, highlighting its pleiotropic regulatory roles.
In Jurkat T lymphocytes, GSK3A functions complement its paralog GSK3B, modulating T cell receptor-induced NFAT and CREB activation, cell cycle progression, and apoptosis. Dysregulated Wnt/??-catenin and PI3K/AKT/mTOR signaling in T cell acute lymphoblastic leukemia underscores GSK3A as a therapeutic target. These knockout cells enable isogenic dissection of GSK3A’s roles in leukemic growth and immune activation, avoiding GSK3B compensation effects.
Typical applications include Western blotting of GSK3A substrates (e.g., GYS1, ??-catenin), RT-qPCR for Wnt targets, flow cytometry for activation markers, TOPFlash reporter assays, phospho-AKT profiling, and viability/apoptosis screens. This model supports isoform-specific target validation in T cell leukemia, Wnt/insulin crosstalk studies, and preclinical GSK3A inhibitor evaluation. For further information, contact Ascent Research.
